Clinical trials: Long Term Follow-Up
Open Angle Glaucoma, Ocular Hypertension
MINIject Global Long-Term Follow-up Study
The study will assess the long-term (up to 5 years) safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.
- Trial name
- STAR-GLOBAL (NCT04524416)
- Testing
- Minimally invasive glaucoma surgery (MIGS)
- Where
- 9 sites in Colombia, France and 4 more
- Volunteers
- 116 people
- Sponsor
- iSTAR Medical
Spinal Cord Injuries
LTFU Study of Subjects Who Received GRNOPC1
This is a LTFU study for thoracic SCI subjects that were administered GRNOPC1 cells in the main study CP35A007.
- Trial name
- NCT05919563
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Lineage Cell Therapeutics, Inc.
Lung Cancer, Breast Cancer
Iressa Follow-up Trial
The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).
- Trial name
- NCT00357734
- Testing
- Gefitinib
- Where
- 7 sites in Germany
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Alpha-1 Antitrypsin Deficiency
Long-Term Follow-up Study of ADVM-043
ADVM-043-03 is a long-term follow-up (LTFU) study of subjects who participated in the ADVM-043-01 (NCT02168686) multi-center gene therapy clinical study (ADVANCE) that evaluated ADVM-043 for the treatment of Alpha-1 Antitrypsin…
- Trial name
- NCT03804021
- Testing
- No Intervention
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adverum Biotechnologies, Inc.
Epilepsy
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment.
- Trial name
- NCT00175916
- Testing
- Brivaracetam (ucb 34714)
- Where
- 153 sites in United States, Austria and 24 more
- Volunteers
- 853 people
- Sponsor
- UCB Pharma
Thyroid Nodule
Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results
Thyroid nodule pathologies occur frequently and represent a clinical issue for the endocrinologists, surgeons, nuclear physicians as well as the general practitioners.
- Trial name
- NCT00858104
- Testing
- Percutaneous Laser Ablation
- Where
- 4 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Elesta S.R.L.
Hernia, Hernia, Ventral
T-GENVIH-003 LTFU (Long Term Follow Up) Study
The T-GENVIH-003 study will collect additional, longer term performance data of Gentrix® Surgical Matrix used for reinforcement of ventral hernia repairs from a subset population (i.e., the twenty-one minimally invasive surgical…
- Conditions
- Hernia, Hernia, Ventral, Pathological Conditions, Anatomical, Hernia, Abdominal
- Trial name
- NCT06034652
- Testing
- Integra® Gentrix® Surgical Matrix
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Integra LifeSciences Corporation
Hepatitis B, Hepatitis A
Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule
The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 6, 7, 8, 9 and 10 after subjects received their first two doses primary vaccination schedule of combined hepatitis…
- Trial name
- NCT00289744
- Testing
- TWINRIX™ ADULT, Engerix TM
- Where
- Belgium
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is…
- Trial name
- NCT00150709
- Testing
- Levetiracetam
- Volunteers
- 223 people
- Sponsor
- UCB Pharma
Ornithine Transcarbamylase (OTC) Deficiency
Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
Determine the long-term safety of DTX301 following a single intravenous (IV) dose in adults with late-onset ornithine transcarbamylase (OTC) deficiency.
- Trial name
- CAPtivate (NCT03636438)
- Testing
- No Intervention
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 11 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Diabetic Retinopathy, DR
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic…
- Trial name
- NCT05296447
- Testing
- Standard of Care, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hematologic Malignancies, Solid Tumors
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study.
- Trial name
- NCT06925685
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Allogene Therapeutics
Type 1 Gaucher Disease
A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02
This is a multicenter, multinational long-term follow-up study to assess the long-term safety and durability of effect of AVR-RD-02 treatment in subjects who previously received AVR-RD-02 treatment (single dose administration).
- Trial name
- NCT04836377
- Testing
- Safety and efficacy assessments
- Where
- 3 sites in United States, Canada
- Volunteers
- 4 people
- Sponsor
- AVROBIO
Mucopolysaccharidosis IIIA, MPS IIIA
Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
The main objective of this study is to evaluate the safety/tolerability and efficacy of UX111 (previously known as ABO-102) in participants with Mucopolysaccharidosis IIIA (MPS IIIA).
- Conditions
- Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
- Trial name
- NCT04360265
- Testing
- No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 41 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Rheumatoid Arthritis, Psoriatic Arthritis
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or…
- Trial name
- NCT05413044
- Where
- United States
- Volunteers
- 140,706 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Rheumatoid
Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis
The assessment of otelixizumab in rheumatoid arthritis subjects will provide safety, tolerability, pharmacodynamic and pharmacokinetic information which will enable the identification of appropriate safe and well-tolerated dosage…
- Trial name
- NCT01077531
- Testing
- Otelixizumab
- Where
- 7 sites in Russia, Spain and 1 more
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis, Post-traumatic; Arthrosis
Long Term Sidus PMCF
The objectives of this study are to assess the safety and performance of the Sidus Stem-Free Shoulder Arthroplasty System in unilateral primary total shoulder arthroplasty.
- Trial name
- NCT04063943
- Testing
- Sidus Stem-Free Shoulder
- Where
- 7 sites in United States, Canada
- Sponsor
- Zimmer Biomet
Alzheimer's Disease
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
- Trial name
- NCT00934050
- Testing
- ELND005 (scyllo-inositol)
- Where
- 38 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- OPKO Health, Inc.